|13:00||Opening Remarks||李文領 理事長|
|Topic 1: High bleeding risk and choice of stents
What is the preferred stent in patients suffering from ACS with high bleeding risk ?
|13:05||Bio-degradable polymer drug-eluting stents||李政翰||方慶章|
|13:20||Durable polymer drug-eluting stents||施志遠|
|13:35||Drug coating balloon||王宇澄|
|13:50||Rebuttal (each 3 mins)|
|14:05||Special Lecture: Updated anti-thrombotic therapy and choice of P2Y12 inhibitor in Eat-Asia ACS patients with high bleeding risk||劉秉彥||李文領|
|Topic 2: Long-term pharmacological management of chronic coronary syndrome
What is the preferred pharmacological therapy for high ischemic/low bleeding risk CAD in long-term?
|14:35||Standard DAPT and then long-term P2Y12 inhibitor||方修御||郭風裕|
|14:50||Extended DAPT (>30 months)||黃成偉|
|15:05||Low dose Xa-inhibitor on top of aspirin after standard DAPT||陳郁志|
|15:20||Rebuttal (each 3 mins)|
|Topic 3: What is the preferred SINGLE anti-platelet therapy for post-PCI patient beyond period of DAPT?|
|16:20||Rebuttal (each 3 minutes)|
|Topic 4: Long-term pharmacological management for our CAD patients with type 2 DM ?
Which one is the BEST choice for CAD/DM patients in long-term outcomes as add-on therapy?
|16:50||GLP1 receptor agonist||鄧欣一|
|17:05||Rebuttal (each 3 mins)|
|17:15||Closing Remarks||洪大川 主委|